La chaîne d'options affiche les données clés des options sur actions de Nurix Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Nurix Therapeutics..

Nurix Therapeutics (NASDAQ:NRIX) Stock, Chaîne d'Options

Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Nurix Therapeutics Inc

TD Cowen analyst Lance Vitanza initiates coverage on Compass Diversified Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CODI#NYSE">CODI</a>) with a Buy rating and announces Price Target of $34.

News

Price Target

Initiation

Analyst Ratings

CODI

TD Cowen Initiates Coverage On Compass Diversified Hldgs with Buy Rating, Announces Price Target of $34

WIIM

WDAY

Workday shares are trading lower after the company reported Q3 financial results  revised its FY25 subscription revenue guidance. Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $285 to $270.

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) could see significant workforce changes if California Governor Gavin Newsom proceeds with excluding the company from a proposed <a href="https://www.benzinga.com/tech/24/11/42183055/elon-musk-slams-californias-proposal-to-shut-tesla-evs-out-of-consumer-rebates-in-state-this-is-insane">electric vehicle consumer rebate program</a>, according to Dan Ives, analyst at Wedbush Securities.
What Happened: &#8220;You had Jake Paul and Tyson, and now you&#8217;ve got Newsom and Musk—this is gonna be battle,&#8221; Ives told Bloomberg in an interview. &#8220;It&#8217;s a political battle, but Tesla is the only EV manufacturer actually made in California.&#8221;
The analyst suggested that the proposed rebate program exclusion might accelerate job migrations from the company&#8217;s Fremont facility to its Texas headquarters.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Dan Ives, senior equities analyst at Wedbush Securities talks about California Governor Gavin Newsom excluding Tesla&#39;s from a proposed consumer rebate program. Musk calls the proposal &quot;insane&quot; <a href="https://t.co/fetzLuxGOL">https://t.co/fetzLuxGOL</a> <a href="https://t.co/20oDaOLdb7">pic.twitter.com/20oDaOLdb7</a>
&mdash; Bloomberg TV (@BloombergTV) <a href="https://twitter.com/BloombergTV/status/1861437239948939771?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Wedbush maintained its Outperform rating on Tesla shares, with a $400.00 price target, despite the brewing controversy, according <a href="https://in.investing.com/news/analyst-ratings/wedbush-sustains-tesla-stock-target-amid-ca-rebate-concerns-93CH-4546215">to</a> Investing.com. The firm&#8217;s commentary highlights the complex relationship between Tesla CEO Elon Musk and Newsom, which has been strained by previous disagreements, including COVID-related factory shutdowns and Tesla&#8217;s 2021 headquarters relocation.
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a>
What Happened: Governor Newsom&#8217;s proposal aims to reinstate the state&#8217;s Clean Vehicle Rebate program, potentially excluding Tesla to promote market competition. This move comes in anticipation of potential federal EV tax credit eliminations.
Musk swiftly criticized the proposal, calling it &#8220;insane&#8221; and suggesting the decision could damage California&#8217;s economic interests. The dispute echoes ongoing <a href="https://www.benzinga.com/markets/equities/24/07/39815808/elon-musk-claps-back-after-gavin-newsom-shares-donald-trumps-drop-to-your-knees-and-beg-post-abo">tensions between Musk and Newsom</a>, including previous conflicts over state jobs and corporate taxation.
The potential rebate program exclusion could incentivize Tesla to accelerate job transfers from Fremont to its expanding Austin Gigafactory, a prospect Ives warned could significantly impact California&#8217;s manufacturing landscape.
Price Action: Tesla stock closed at $338.23 on Tuesday, down 0.11% for the day. In after-hours trading, the stock rose 0.57. Year-to-date, Tesla&#8217;s stock has surged by 36.15%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">Fed Minutes Reveal &#8216;Confidence&#8217; In Inflation Reduction, Yet Flag Divergent Views On Interest Rate Path Ahead</a></li>
</ul>
Gavin Newsom Elon Musk &#x7C; Photos courtesy: Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

Markets

TSLA

Dan Ives Compares Newsom Vs. Musk Battle To Jake Paul Vs. Tyson, Warns Of California's Job Migration Risk To Texas

Dragonfly Energy Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) saw a significant drop of 10.71% in its stock price on Tuesday, closing at $3.50. After-hours trading showed a further decline of 4.57%. 
What Happened: This comes despite the company announcing the release of its new Battle Born smart lithium batteries with Dragonfly IntelLigence technology. 
The launch coincides with the Black Friday sales event, offering discounted prices through Cyber Monday. Dragonfly Energy&#8217;s batteries feature advanced monitoring capabilities, providing real-time data and alerts for enhanced system performance and compliance with industry standards.
DFLI is down 34.33% year-to-date, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42206056/bitcoin-ethereum-dogecoin-tumble-as-diamond-hands-lock-in-gains-analyst-anticipates-strong-buyback-pressure-to-follow-sell-pressure">Bitcoin, Ethereum, Dogecoin Tumble As &#8216;Diamond Hands&#8217; Lock In Gains: Top Analyst Anticipates BTC Rebound</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

DFLI

Dragonfly Energy Sees Over 10% Decline As New Smart Lithium Batteries Launch Amid Black Friday Event

LDTC

LeddarTech To Demonstrate Latest AI-Driven Automotive Software In Collaboration With Arm And Texas Instruments At CES 2025, Las Vegas

DELL

Dell Technologies shares are trading lower after the company reported worse-than-expected Q3 sales results.

BTIG analyst Marie Thibault upgrades Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) from Neutral to Buy and announces $26 price target.

Upgrades

EMBC

BTIG Upgrades Embecta to Buy, Announces $26 Price Target

Jefferies analyst Omar Nokta maintains Golden Ocean Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGL#NASDAQ">GOGL</a>) with a Hold and lowers the price target from $12.5 to $12.

GOGL

Jefferies Maintains Hold on Golden Ocean Group, Lowers Price Target to $12

Benchmark analyst Fawne Jiang maintains H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) with a Buy and lowers the price target from $53 to $48.

HTHT

Benchmark Maintains Buy on H World Group, Lowers Price Target to $48

Shares of&nbsp;CrowdStrike Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) dropped by 6.14% in pre-market trading on Wednesday, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>. This decline followed a weaker-than-anticipated earnings forecast for the upcoming quarter, despite the company surpassing Wall Street estimates for the third quarter.
What Happened: CrowdStrike projected adjusted earnings of $0.84 to $0.86 per share for the fiscal fourth quarter, missing Wall Street&#8217;s expectation of $$0.86 cents per share. Despite this, the cybersecurity firm reported record revenue of $1.01 billion in the third quarter, exceeding the consensus estimate of $982.36 million. Adjusted earnings stood at $0.93 per share, surpassing analyst predictions of $0.81 per share.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42154817/crypto-analyst-sees-shiba-inu-surging-more-than-2000-in-coming-rally?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crypto Analyst Sees Shiba Inu Surging More Than 2,000% In Coming Rally</a>
The company&#8217;s recent performance follows a problematic <a href="https://www.benzinga.com/news/24/07/39870313/microsoft-crowdstrike-issue-caused-largest-it-outage-in-history-showing-how-much-we-depend-on-a-hand">software update in July </a>that caused global computer crashes. Investors have been closely monitoring&nbsp;CrowdStrike&nbsp;for signs of recovery since the incident. While the third-quarter results were strong, the cautious outlook for the upcoming quarter has tempered investor enthusiasm.
Meanwhile, post the earnings, Needham &amp; Company upgraded the price target from $360 to $420 while HSBC has downgraded to $347, as per <a href="https://pro.benzinga.com">Benzinga Pro</a> data.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/CRWD/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27072909/Screenshot-2024-11-27-at-5.59.02%E2%80%AFPM-1024x394.png" alt="" class="wp-image-667216" /></a></figure>
Why It Matters: The recent earnings report highlights&nbsp;CrowdStrike&#8217;s&nbsp;ability to recover from the July software update fallout, which had significant global repercussions. The company has consistently <a href="https://www.benzinga.com/news/earnings/24/11/42202105/crowdstrike-beats-q3-earnings-revenue-estimates-cybersecurity-company-highlights-incredible-success-retaining-customers-following-it-outage">exceeded analyst estimates </a>since its public debut in 2019, showcasing resilience and strong customer retention.
Despite the technical challenges earlier in the year, CrowdStrike has<a href="https://www.benzinga.com/news/earnings/24/11/42209469/crowdstrike-stocks-technical-analysis-shows-bullish-trend-as-it-navigates-july-fallout-to-deliver-record-q3-revenue-heres-more"> demonstrated a bullish trend</a>. Despite falling in premarket trading on Wednesday, at $344 a piece, CrowdStrike's stock is above its 20, 50, and 200-day simple moving averages, suggesting a largely bullish trend.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/11/42206056/bitcoin-ethereum-dogecoin-tumble-as-diamond-hands-lock-in-gains-analyst-anticipates-strong-buyback-pressure-to-follow-sell-pressure?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Tumble As &#8216;Diamond Hands&#8217; Lock In Gains: Top Analyst Anticipates BTC Rebound</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Pre-Market Outlook

General

CRWD

CrowdStrike Shares Fall 6% Despite Beating Q3 Estimates: What's Going On?

Grant Cardone is getting vocal about housing. The real estate mogul and entrepreneur took to Twitter with strong words on the topic. &#8220;The average rate on a 30-year fixed mortgage is 6.84% this week,&#8221; <a href="https://x.com/GrantCardone/status/1859961992460816613">he tweeted,</a> citing Freddie Mac data. &#8220;The 7th weekly increase over the past eight weeks. If this continues, homeownership is OVER in America.&#8221;
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>
Bold claim? Yeah, but Cardone's not wrong about rates climbing fast. Mortgage rates have been creeping up for months. They're at levels not seen in over two decades. For context, the 30-year fixed mortgage rate averaged just 3% in 2021.. Today, it's more than double that. That spike is slamming potential homebuyers. Monthly payments are skyrocketing and dreams of owning a home feel like a pipe dream.
Cardone is known for his real estate empire and no-nonsense business advice. He has a long history of talking about housing. He's built his career around multifamily real estate. He also owns thousands of apartment units across the U.S. and has never been shy about saying <a href="https://www.benzinga.com/markets/24/11/42146196/homeownership-vs-renting-why-grant-cardone-thinks-the-american-dream-is-a-terrible-investment">homeownership isn't for everyone.</a> But this time, it's different. He's not just talking about the challenges of owning a home. He's saying rising rates could kill the American dream altogether.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
He didn't stop there. &#8220;America should have the best housing &amp; the lowest interest rates in the world,&#8221; he added. A big statement, but Cardone has a point. Higher rates don't just hurt buyers. They ripple through the entire economy. Housing is a massive driver of growth. When people can't buy, homebuilders stop building and industries like construction and home goods take a hit.
Cardone's tweet reflects the frustration of many. Rising rates are making housing <a href="https://www.benzinga.com/real-estate/24/10/41166593/grant-cardone-dispels-the-american-dream-of-homeownership-citing-mortgage-payments-as-double-the-ren">unaffordable for millions. </a>In 2021, the average 30-year fixed mortgage rate was 3%. A $300,000 mortgage at 3% costs around $1,265 a month. At today's rates? That same loan will set you back over $2,000. That's not chump change.
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
This isn't just about numbers, either. For decades, homeownership has been a symbol of stability and success in America. But now, it's slipping further out of reach. Younger generations are especially hurting. Millennials and Gen Z, already burdened by student loans and rising living costs, are being hit the hardest.
The solution? That's up for debate. Some experts say the Federal Reserve needs to ease up on rate hikes. Others argue for more affordable housing options. Cardone's take? He didn't spell it out this time, but knowing him, he'd probably say it's time to think bigger and <a href="https://www.facebook.com/grantcardonefan/videos/invest-in-assets-that-produce-cash-flow/461800760050933/">focus on cash flow</a>. That could mean renting, investing or finding new ways to build wealth.
One thing's clear: If rates keep climbing, the housing market will keep feeling the heat. And for many, homeownership might be &#8220;OVER,&#8221; just like Cardone said.
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Real Estate

Freddie Mac Reports 6.84% Mortgage Rate As Grant Cardone Warns Of Homeownership Crisis

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dip to $93,000 can be attributed to pressure from a combination of macroeconomic shifts, technical signals and on-chain trends, according to the latest note by 10x Research.
Despite this, the long-term outlook for 2025 appears optimistic, aligning with Bitcoin's historical cycles and broader economic trends, the analysts report.
The impact of rate cuts 
<ol>
<li></li>
</ol>
One of the primary drivers of Bitcoin's decline is the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">Federal Reserve's cautious approach</a> to monetary easing.
"The FOMC minutes hint at a pause in monetary easing," the report notes, highlighting how this shift removes a critical tailwind that has historically supported Bitcoin's growth. 
Without the added boost from loose fiscal policies, Bitcoin has lost some of its upward momentum, exposing vulnerabilities in its price action.
Global liquidity taps start closing
Another factor impacting Bitcoin is its close correlation with <a href="https://www.benzinga.com/24/11/42170458/crude-oil-down-2-chicago-fed-national-activity-index-falls-in-october">global money supply changes</a>.
The report points out that "over the past 12 months, a clear correlation has emerged, with changes in money supply leading Bitcoin's movements by approximately ten weeks." 
This lagging effect has played out recently, as Bitcoin peaked in November following earlier monetary policy adjustments. 
However, with the pace of monetary expansion slowing, Bitcoin has struggled to maintain its previous trajectory.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42198909/trump-linked-crypto-platform-world-liberty-financial-appoints-justin-sun-as-advisor-after-30-million-investment">Trump-Linked Crypto Platform World Liberty Financial Appoints Justin Sun As Advisor After $30 Million Investment</a>
Technical indicators
<a href="https://www.benzinga.com/money/what-you-need-to-know-about-technical-analysis">Technical indicators</a> also reveal why Bitcoin's price has faltered.
According to the report, Bitcoin "confirmed bearish daily reversal signals in play, with weekly signals likely to follow," suggesting a potential correction from overbought levels. 
Analysts have identified critical support levels at $89,000 and $75,000, which will be key in determining whether Bitcoin can stabilize and regain momentum.
On-chain metrics offer additional context. 
The realized profit-loss ratio and changes in long-term holder positions have signaled increased selling pressure from experienced investors. 
The report notes, "A meaningful signal only emerges when this ratio reverses lower—indicating that longer-term holders are slowing their profitable coin sales."
This suggests that selling momentum could ease in the near future, paving the way for consolidation and eventual recovery.
What&#8217;s Next
Looking ahead, the report offers a cautiously optimistic view. 
While December has historically been a bullish month for Bitcoin, the broader outlook for 2025 remains the real focus. 
The report reinforces this sentiment, stating, "This pattern has consistently played out during Bitcoin&#8217;s short history, pointing to a continued bullish outlook for 2025." 
With cyclical trends and potential macroeconomic shifts aligning, Bitcoin may be poised for another strong performance in <a href="https://www.benzinga.com/money/bitcoin-price-prediction">the years ahead</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42196910/pantera-bitcoin-fund-hits-1000x-return-predicts-btc-at-740000-by-2028">Pantera Bitcoin Fund Hits 1,000X Return, Predicts BTC At $740,000 By 2028</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin At $93,000—Crash Or Pause? 'Bullish Outlook For 2025,' Says 10x Research

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

ARWR

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $295 to $325.

ADSK

Rosenblatt Maintains Buy on Autodesk, Raises Price Target to $325

AMBA: 29% &#x7C; <a href="https://www.benzinga.com//node/42201842">Ambarella shares are trading higher after the company reported a year-over-year increase in Q3 revenue results.</a>
&nbsp;
TRNR: 86% &#x7C; <a href="https://www.benzinga.com//node/42210976">Interactive Strength Receives Letter Confirming Demonstrated Compliance With Nasdaq Listing Rule, Which Successfully Concludes Hearings Panel Appeal Process That Began In May</a>
&nbsp;
DELL: -13% &#x7C; <a href="https://www.benzinga.com//node/42201722">Dell Technologies shares are trading lower following a Q3 revenue miss.</a>

Movers

Trading Ideas

AMBA

TRNR

Market-Moving News for November 27th

Benchmark analyst Christopher Kuhn maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Buy and raises the price target from $32 to $34.

SNDR

Benchmark Maintains Buy on Schneider National, Raises Price Target to $34

Legendary investor&nbsp;Warren Buffett&nbsp;has a piece of critical advice for parents that he believes they should follow, regardless of their wealth status.
What Happened: In a recent letter, the Berkshire Hathaway CEO advised parents to not just write their will but also discuss it with their children.
"Be sure each child understands both the logic for your decisions and the responsibilities they will encounter upon your death," the Oracle of Omaha said.
This, Buffett says, essentially ensures that there is clarity about the inheritance between parents and their children, reducing the chances of disputes. This is especially important when parents are no longer there to resolve differences over matters such as these.
"If any have questions or suggestions, listen carefully and adopt those found sensible. You don't want your children asking ‘Why?' in respect to
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42197276/anthony-scaramucci-trump-win-is-the-greatest-political-comeback-in-us-history-crypto-surge-following-it-was-3-years-overdue?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Anthony Scaramucci: Trump Win Is &#8216;The Greatest Political Comeback In US History'</a>
Buffett&#8217;s letter also recounted instances where families were torn apart due to unclear testamentary directives.
He encouraged parents to invite their adult children to discuss the will, ensuring transparency and understanding.
Why It Matters: This advice from Buffett aligns with his recent actions, including&nbsp;<a href="https://www.benzinga.com/news/24/11/42177867/warren-buffett-announces-new-charitable-gifts-updates-plans-for-150b-fortune-billionaire-wants-to-help-others-given-a-very-short-straw-at-birth">announcing new charitable donations</a>&nbsp;and updates to his $150 billion fortune.
Buffett has been converting Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) shares to make these donations, emphasizing his commitment to philanthropy.
Buffett&#8217;s family dynamics also reflect his philosophy. His daughter-in-law, Mary Buffett, once thought she would receive &#8220;free candy&#8221; upon marrying his son, but learned there was no such thing with Warren, highlighting his emphasis on self-reliance and integrity.
This perspective is consistent with his hiring philosophy, where he values&nbsp;<a href="https://www.benzinga.com/startups/24/11/41976499/warren-buffett-shares-three-key-traits-to-look-for-when-hiring-says-that-without-integrity-the-other-two-will-kill-you">integrity above all</a>&nbsp;other traits.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42155884/economist-slams-doges-simplistic-approach-to-government-spending-questions-super-bowl-ad-criticism?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Economist Slams DOGE: Tells Elon Musk-Led Initiative To &#8216;Do Your Legal Job Well&#8217; Amid Super Bowl Ad Spending Clash</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Personal Finance

Warren Buffett Says Parents Should Do This One Thing Before They Die, Whether They Are Rich Or Not

Guidance

Symbotic Cuts Q1'FY25 Revenue Outlook From $495M - $515M To $480M - $500M (Est $503.579M)

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and maintains $385 price target.

Rosenblatt Maintains Buy on CrowdStrike Holdings, Maintains $385 Price Target

As a result, gross profit, income (loss) before income tax, net income (loss) and adjusted EBITDA1 were also impacted. The company estimates the total impact of correcting these errors will be to lower system revenue, system gross profit, income (loss) before income tax, and adjusted EBITDA by $30 million to $40 million for fiscal year 2024 compared to the financial results released on November 18, 2024.

Symbotic Says Identified Errors In Its Revenue Recognition Related To Cost Overruns

The latest announcement is out from Nurix Therapeutics ( ($NRIX) ). Nurix Therapeutics, a clinical-stage biopharmaceutical company, has appointed A...

Nurix Therapeutics Appoints Anil Kapur to Board

H.C. Wainwright analyst Robert Burns raised the firm's price target on Nurix Therapeutics (NRIX) to $30 from $26 and keeps a Buy rating on the shar...

Nurix Therapeutics price target raised to $30 from $26 at H.C. Wainwright

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $32.0...

Promising Prospects for Nurix Therapeutics: Buy Rating Backed by Strong Data on NX-5948

Needham analyst Gil Blum maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $29.00. Gil Blum ha...

Promising Data on Nurix Therapeutics' NX-5948 Supports Buy Rating for Waldenstrom's Macroglobulinemia Treatment

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Nurix Therapeutics (NRIX – Research Report), with a price target of...

Barclays Gives a Buy Rating to Nurix Therapeutics (NRIX)

UBS initiated coverage of Nurix Therapeutics (NRIX) with a Buy rating and $35 price target The firm launched coverage of SMID cap biotech sector wi...

Nurix Therapeutics initiated with a Buy at UBS

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $29.00. Gil Bl...

Promising Efficacy and Safety of Nurix Therapeutics' NX-5948 Justifies Buy Rating

Nurix Therapeutics (NRIX) announced that the European Medicines Agency, or EMA, has granted PRIME designation for NX-5948, a highly selective degra...

Nurix Therapeutics announces PRIME designation for NX-5948 from EMA

BPMC

CATX

CGEM

CGON

HAFC

IDYA

IMCR

IOVA

JANX

KURA

MRUS

NRIX

NUVL

SIRI

SNDX

Press Releases

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

Earnings

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Management

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Health Care

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Comments

Nurix Therapeutics

Nurix Therapeutics (NRIX) Options

Nurix Therapeutics (NASDAQ:NRIX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL